Day: March 17, 2026

CHARLOTTE, N.C., March 17, 2026 (GLOBE NEWSWIRE) — Terrestrial Energy Inc. (NASDAQ: IMSR) will report its fourth quarter and full year 2025 earnings before the market opens on Monday, March 30th, 2026, and will hold a conference call at 8:30am ET that day. A live webcast of the conference call will be made available on the Events section of Terrestrial Energy’s investor relations website at https://ir.terrestrialenergy.com. The earnings release and presentation will also be posted to the investor relations website prior to the conference call. The live conference call may also be accessed by dialing (877) 407-0779 or (201) 389-0914. For those unable to listen to the live conference call, a replay will be available after the call through the archived webcast in the Events section of Terrestrial Energy’s investor relations website...

Reported positive Phase 2b RewinD-LB clinical data at CTAD 2025; additional analyses to be presented at AD/PD 2026 Obtained alignment with FDA and global regulators for planned Phase 3 trial design in patients with DLB and selected Phase 3 formulation, dose and dosing regimen Multiple potential catalysts anticipated in the second half of 2026, including initiation of the planned Phase 3 trial, topline data from Phase 2a ischemic stroke recovery trial, initial topline data from Phase 2a primary progressive aphasia trial, and initiation of EXPERTS-ALS trial in Amyotrophic Lateral Sclerosis BOSTON, March 17, 2026 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical-stage biotechnology company developing treatments for age-related brain disorders (CervoMed or the Company), today reported financial results for the fourth quarter...

Recent milestones include strategic collaboration with C-Further to advance PRAME-targeted iNKT cell therapy for pediatric cancers, with meaningful downstream commercial revenue potential NEW YORK, March 17, 2026 (GLOBE NEWSWIRE) — MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and immune disorders, today announced that it will report financial results for the fourth quarter and full year ended December 31, 2025, before the market opens on Tuesday, March 31, 2026. The company will host a conference call and webcast at 8:30 a.m. ET that morning to review financial results and provide a corporate update on clinical progress, platform expansion, and strategic initiatives across its iNKT cell therapy portfolio. The...

Sherman Oaks, CA, March 17, 2026 (GLOBE NEWSWIRE) — Xsolla SPAC 1, a newly organized special purpose acquisition company formed as a Cayman Islands exempted company (Nasdaq: XSLLU) (the “Company”), announced today that, commencing March 18, 2026, holders of the units sold in the Company’s initial public offering may elect to separately trade the Company’s Class A ordinary shares and warrants included in the units. No fractional warrants will be issued upon separation of the units and only whole warrants will trade. The Class A ordinary shares and warrants that are separated will trade on The Nasdaq Stock Market under the symbols “XSLL” and “XSLLW,” respectively. Those units not separated will continue to trade on The Nasdaq Stock Market under the symbol “XSLLU.” Holders of units will need to have their brokers contact Odyssey Transfer...

WINNIPEG, Manitoba, March 17, 2026 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) announces that Frontiers in Antibiotics has published a peer-reviewed article authored by researchers from Kane Biotech and the University of Manitoba, detailing important scientific advancements in the fight against antibiotic-tolerant biofilms. Key messages of the article as it relates to Kane’s revyve wound gel include:revyve Antimicrobial Wound Gel demonstrated strong activity against antibiotic-tolerant biofilms, a major barrier in the treatment of chronic wounds. In both in vitro and ex vivo models, revyve eliminated mature Staphylococcus aureus and Pseudomonas aeruginosa biofilms, even after they had developed high levels of antibiotic tolerance. Following antibiotic pre-treatment, which generated highly antibiotic-tolerant...